NCT03355365View on ClinicalTrials.gov

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

February 9, 2023

Study Completion Date

April 17, 2023

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Intrathecal MSC-NP injection

MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.

OTHER

Intrathecal saline injection

Placebo

Trial Locations (1)

10019

Tisch MS Research Center of New York, New York

All Listed Sponsors
lead

Tisch Multiple Sclerosis Research Center of New York

OTHER

NCT03355365 - Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter